Items where authors include "Attard, G."

Article

Jones, C., Dutey-Magni, P., Murphy, L.R. et al. (17 more authors) (2025) Fracture-related hospitalisations in newly diagnosed high-risk localised or metastatic hormone-sensitive prostate cancer: secondary analysis of the STAMPEDE phase III trials of docetaxel and zoledronic acid using healthcare systems data. Annals of Oncology, 36 (11). pp. 1331-1341. ISSN 0923-7534

Leone, G., Wong, Y.N.S., Jones, R.J. et al. (25 more authors) (2025) Nivolumab and Ipilimumab for Metastatic Castration-Resistant Prostate Cancer With an Immunogenic Signature: The Multicenter, Two-Cohort, Phase II NEPTUNES Study. Journal of Clinical Oncology, 43 (28). pp. 3070-3080. ISSN 0732-183X

Parker, C.C., James, N.D. orcid.org/0000-0002-7314-8204, Brawley, C.D. orcid.org/0000-0003-3641-278X et al. (43 more authors) (2022) Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial. PLOS Medicine, 19 (6). e1003998. ISSN 1549-1277

Clarke, N.W., Ali, A., Ingleby, F.C. et al. (47 more authors) (2019) Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Annals of Oncology, 30 (12). pp. 1992-2003. ISSN 0923-7534

Pezaro, C., Mukherji, D., Tunariu, N. et al. (8 more authors) (2013) Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer. British Journal of Cancer, 109 (2). pp. 325-331. ISSN 0007-0920